Novo Nordisk A/S Stock price

Equities

NOVO B

DK0062498333

Pharmaceuticals

Delayed Nasdaq Copenhagen 10:59:49 2023-09-27 am EDT Intraday chart for Novo Nordisk A/S 5-day change 1st Jan Change
647.50 DKK -0.40% -2.28% +38.06%
Sales 2023 * 224 B 31,604 M Sales 2024 * 264 B 37,236 M Capitalization 2896 B 408 B
Net income 2023 * 79,256 M 11,169 M Net income 2024 * 91,729 M 12,927 M EV / Sales 2023 *
12,8x
Net cash position 2023 * 15,517 M 2,187 M Net cash position 2024 * 33,328 M 4,697 M EV / Sales 2024 *
10,8x
P/E ratio 2023 *
36,5x
P/E ratio 2024 *
31,0x
Employees -
Yield 2023 *
1,27%
Yield 2024 *
1,49%
Free-Float80.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.40%
1 week+0.08%
Current month+1.65%
1 month+1.33%
3 months+20.47%
6 months+23.45%
Current year+38.06%
More quotes
1 week
630.00
Extreme 630
663.40
1 month
630.00
Extreme 630
690.30
Current year
448.25
Extreme 448.25
690.30
1 year
369.00
Extreme 369
690.30
3 years
203.45
Extreme 203.45
690.30
5 years
132.58
Extreme 132.575
690.30
10 years
89.80
Extreme 89.8
690.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 2016
Director of Finance/CFO 52 2018
Chief Operating Officer 53 2016
Members of the board TitleAgeSince
Director/Board Member 67 2018
Director/Board Member 61 2018
Chairman 61 2018
More insiders
Date Price Change Volume
23-09-27 647.50 -0.40% 2,086,701
23-09-26 650.10 +2.02% 3,070,633
23-09-25 637.20 -0.65% 2,109,465
23-09-22 641.40 -0.14% 2,401,391
23-09-21 642.30 -3.06% 2,711,767

Delayed Quote Nasdaq Copenhagen, September 27, 2023 at 10:59 am EDT

More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes treatment products (78.9%); - rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.; - obesity treatment products (9.5%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
647.50DKK
Average target price
644.48DKK
Spread / Average Target
-0.47%
Consensus
1st Jan change Capi. (M$)
+38.06% 412 B $
-11.06% 383 B $
+50.27% 495 B $
-5.25% 272 B $
-6.32% 267 B $
-13.25% 220 B $
-0.89% 210 B $
+10.61% 210 B $
-37.35% 183 B $
+2.41% 144 B $
Other Pharmaceuticals
  1. Markets
  2. Equities
  3. Stock Novo Nordisk A/S - Nasdaq Copenhagen
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer